Diffusion Pharmaceuticals Appoints Dr. Robert Ruffolo to Board of Directors

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer and other hypoxia-related diseases, today announced the appointment of Robert R. Ruffolo, Jr., Ph.D., to its Board of Directors, effective immediately.

This entry was posted in Recent Development News: Q3 - 2017, Recent Developments. Bookmark the permalink.
Read Full Article »